US Army Will Use Metabolon Technology to Study Anthrax Vaccine in Humans | GenomeWeb
NEW YORK (GenomeWeb News) — Metabolon said yesterday that the US Army Medical Research Institute of Infectious Diseases will use its metabolomics platform to study the effects of the AVA anthrax vaccine in humans.
Metabolon's chief science officer Mike Milburn said the collaboration on the FDA-approved vaccine is the “first large-scale metabolomics study of human subjects given a vaccine.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.